Global state ‐ relapse or worsening ‐ medium term Numbers of participants experiencing relapse/worsening · patients with schizophrenia
TRIFLUOPERAZINE may leads to lower global state ‐ relapse or worsening ‐ medium term Numbers of… compared with PLACEBO (low certainty).
1 finding from 1 review
Mental state ‐ any clinically significant response in psychotic symptoms (as defined by each study) ‐ medium term Numbers of participants experiencing 'intensified symptoms' · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes mental state ‐ any clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Severe adverse effects ‐ short term Numbers of participants leaving the studies due to severe adverse effects · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes severe adverse effects ‐ short term Numbers of participants leaving… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour ‐ any clinically significant agitation or distress ‐ medium term As defined by each study · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes behaviour ‐ any clinically significant agitation or distress ‐… compared with PLACEBO (very low certainty).
1 finding from 1 review
Economic outcomes · patients with schizophrenia
1 finding from 1 review
Psychiatric hospital admission: psychiatric admission Numbers admitted · patients with routine care of people with severe mental illness
User‐held information showed no clear difference in psychiatric hospital admission: psychiatric admission Numbers admitted compared with standard information (moderate certainty).
1 finding from 1 review
Psychiatric hospital admission: compulsory admission Numbers admitted · patients with routine care of people with severe mental illness
User‐held information showed no clear difference in psychiatric hospital admission: compulsory admission Numbers admitted compared with standard information (moderate certainty).
1 finding from 1 review
Death: causes other than suicide ‐ not reported · patients with routine care of people with severe mental illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Violence ‐ not reported · patients with routine care of people with severe mental illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: psychopathology · patients with routine care of people with severe mental illness
1 finding from 1 review
Satisfaction with health care · patients with routine care of people with severe mental illness
1 finding from 1 review
Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes global state: relapse medium term (3‐12 months) Clinical diagnoses compared with PLACEBO (very low certainty).
1 finding from 1 review
Mental state: presence of first‐rank symptoms medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in mental state: presence of first‐rank symptoms medium term (3‐12… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effectsParkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) medium term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effects Parkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE + ANY ANTIPSYCHOTIC may leads to lower global state: relapsemedium term (3‐12 months) Clinical diagnoses compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found